# Safety and Efficacy Study of Triamcinolone Acetonide DuraPeel to Treat Hand Dermatitis

> **NCT00890968** · PHASE2 · COMPLETED · sponsor: **ZARS Pharma Inc.** · enrollment: 56 (actual)

## Conditions studied

- Hand Dermatoses

## Interventions

- **DRUG:** Triamcinolone Acetonide (TAC) DuraPeel
- **DRUG:** Placebo DuraPeel

## Key facts

- **NCT ID:** NCT00890968
- **Lead sponsor:** ZARS Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2009-06
- **Final completion:** 2009-08
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2012-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00890968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00890968, "Safety and Efficacy Study of Triamcinolone Acetonide DuraPeel to Treat Hand Dermatitis". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00890968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*